Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Immunotherapy|July 20, 2010
MAGE A3 antigen-specific cancer immunotherapeuticNir Peled, Ana B Oton, Fred R Hirsch, et al.Orphanet Journal of Rare Diseases|October 15, 2025
The impact of desmoid tumors: insights from the Desmoid Tumor Research Foundation Natural History Study, 2017-2023Amanda Lucas, Shengfan Zhou, Lynne Hernandez, et al.Expert Review of Pharmacoeconomics & Outcomes Research|April 26, 2023
Disease and economic burden of surgery in desmoid tumors: a reviewMaria M Fernandez, Timothy Bell, Brad Tumminello, et al.Current Medical Research and Opinion|December 18, 2020
Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United StatesLisa M Hess, Zhanglin Lin Cui, Xiaohong Ivy Li, et al.Lung Cancer (Amsterdam, Netherlands)|January 23, 2010
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancerRobert C Doebele, Ana B Oton, Nir Peled, et al.Journal of Managed Care & Specialty Pharmacy|May 23, 2017
Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung CancerLisa M Hess, Anthony Louder, Katherine Winfree, et al.European Journal of Haematology|June 25, 2008
Proteomics analysis in post-transplant lymphoproliferative disordersYazan Alsayed, Xavier Leleu, Alexey Leontovich, et al.Advances in Therapy|July 12, 2023
Desmoid Tumors: A Comprehensive ReviewMeryem Bektas, Timothy Bell, Shahnaz Khan, et al.Journal of Medical Economics|May 24, 2017
Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040Lisa M Hess, Zhanglin Lin Cui, Yixun Wu, et al.Journal of Medical Economics|April 21, 2018
Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United StatesLisa M Hess, Zhanglin Lin Cui, Xiaohong Ivy Li, et al.Pageof 3